Michael McElhaugh is the Interim President and Chief Executive Officer at Arbutus Biopharma Corp, a biopharmaceutical company focused on discovering, developing, and commercializing a cure for people with chronic hepatitis B virus infection. With a robust background in the biopharmaceutical industry, McElhaugh has held various leadership roles that have prepared him for his current position. Prior to joining Arbutus Biopharma, he served as the Chief Operating Officer at the company, where he played a pivotal role in overseeing the company's operations and strategic initiatives. Before his tenure at Arbutus Biopharma, McElhaugh accumulated extensive experience in the biopharmaceutical sector, working with several notable companies. He spent over a decade at Merck & Co., where he held multiple senior management positions, including Vice President of Manufacturing and Supply. During his time at Merck, McElhaugh was instrumental in driving the company's operational excellence and ensuring the timely delivery of life-saving medications to patients worldwide. His strategic vision and operational expertise have been key factors in his successful transition to the role of Interim President and CEO at Arbutus Biopharma. In his current role at Arbutus Biopharma, McElhaugh is responsible for leading the company through a critical phase of growth and development. He oversees the company's efforts to advance its pipeline of innovative therapies for chronic hepatitis B and other liver diseases. Under his leadership, Arbutus Biopharma continues to make significant strides in its mission to provide a functional cure for hepatitis B, collaborating with leading researchers and healthcare professionals to bring new treatment options to patients in need. McElhaugh's dedication to improving patient outcomes and his commitment to scientific excellence make him a valuable asset to the company and the broader biopharmaceutical community.